Abstract
The intramembrane-cleaving proteases (I-CliPs) are necessary for the proteolytic cleavage of several transmembrane proteins and initiation of divergent signalling events. The tetrameric γ-secretase protease complexes, comprised of presenilin and three other subunits, represent a major subclass of the I-CliPs. The γ-secretase protease complexes are involved in regulated intramembrane proteolysis, an evolutionary conserved and important signal transduction process encompassing the sequential proteolysis of transmembrane substrates that are central to many physiological processes, including embryonic development, haematopoiesis, and normal functioning of the nervous and immune systems. Deregulated intramembrane proteolysis of certain substrates is proposed to be associated with neurodegeneration, cancer and impaired immune function. In this chapter, we summarise the major biochemical and functional properties (structure, catalytic mechanisms, substrate specificities, and regulation) of the γ-secretase protease complexes. We also present evidence for a role of γ-secretase protease complexes in neurodegeneration, cancer and inflammatory disease and consider the use of γ-secretase inhibitors as prospective therapeutics in several diseases.
This is a preview of subscription content, log in via an institution.
References
Brown MS, Ye J, Rawson RB et al (2000) Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100(4):391–398
Lichtenthaler SF, Haass C, Steiner H (2011) Regulated intramembrane proteolysis—lessons from amyloid precursor protein processing. J Neurochem 117(5):779–796
Schroder B, Saftig P (2016) Intramembrane proteolysis within lysosomes. Ageing Res Rev
Lemberg MK, Menendez J, Misik A et al (2005) Mechanism of intramembrane proteolysis investigated with purified rhomboid proteases. EMBO J 24(3):464–472
Jurisch-Yaksi N, Sannerud R, Annaert W (2013) A fast growing spectrum of biological functions of gamma-secretase in development and disease. Biochim Biophys Acta 1828(12):2815–2827
Langosch D, Scharnagl C, Steiner H et al (2015) Understanding intramembrane proteolysis: from protein dynamics to reaction kinetics. Trends Biochem Sci 40(6):318–327
Duggan SP, McCarthy JV (2016) Beyond gamma-secretase activity: the multifunctional nature of presenilins in cell signalling pathways. Cell Signal 28(1):1–11
Hurst TP, Coleman-Vaughan C, Patwal I et al (2016) Regulated intramembrane proteolysis, innate immunity and therapeutic targets in Alzheimer’s disease. AIMS Mol Sci 3(2):138–157
Sannerud R, Annaert W (2009) Trafficking, a key player in regulated intramembrane proteolysis. Semin Cell Dev Biol 20(2):183–190
Lichtenthaler SF, Steiner H (2007) Sheddases and intramembrane-cleaving proteases: RIPpers of the membrane. Symposium on Regulated Intramembrane Proteolysis. EMBO Rep 8(6):537–541
Edwards DR, Handsley MM, Pennington CJ (2008) The ADAM metalloproteinases. Mol Aspects Med 29(5):258–289
van Hinsbergh VWM, Koolwijk P (2008) Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res 78(2):203–212
Lin CY, Tseng IC, Chou FP et al (2008) Zymogen activation, inhibition, and ectodomain shedding of matriptase. Front Biosci 13:621–635
Morohashi Y, Tomita T (2013) Protein trafficking and maturation regulate intramembrane proteolysis. Biochimica et Biophysica Acta (BBA)—Biomembranes 1828(12):2855–2861
McCarthy JV, Twomey C, Wujek P (2009) Presenilin-dependent regulated intramembrane proteolysis and gamma-secretase activity. Cell Mol Life Sci 66(9):1534–1555
De Strooper B, Saftig P, Craessaerts K et al (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391(6665):387–390
De Strooper B, Annaert W, Cupers P et al (1999) A presenilin-1-dependent [gamma]-secretase-like protease mediates release of Notch intracellular domain. Nature 398(6727):518–522
Guruharsha KG, Kankel MW, Artavanis-Tsakonas S (2012) The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet 13(9):654–666
Marambaud P, Shioi J, Serban G et al (2002) A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 21(8):1948–1956
Fluhrer R, Grammer G, Israel L et al (2006) A [gamma]-secretase-like intramembrane cleavage of TNF[alpha] by the GxGD aspartyl protease SPPL2b. Nat Cell Biol 8(8):894–896
Elzinga BM, Twomey C, Powell JC et al (2009) Interleukin-1 receptor type 1 is a substrate for gamma-secretase-dependent regulated intramembrane proteolysis. J Biol Chem 284(3):1394–1409
Kuhn PH, Marjaux E, Imhof A et al (2007) Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase. J Biol Chem 282(16):11982–11995
Twomey C, Qian S, McCarthy JV (2009) TRAF6 promotes ubiquitination and regulated intramembrane proteolysis of IL-1R1. Biochem Biophys Res Commun 381(3):418–423
McElroy B, Powell JC, McCarthy JV (2007) The insulin-like growth factor 1 (IGF-1) receptor is a substrate for gamma-secretase-mediated intramembrane proteolysis. Biochem Biophys Res Commun 358(4):1136–1141
Sturtevant MA, Roark M, Bier E (1993) The Drosophila rhomboid gene mediates the localized formation of wing veins and interacts genetically with components of the EGF-R signaling pathway. Genes Dev 7(6):961–973
Ni CY, Murphy MP, Golde TE et al (2001) gamma-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294(5549):2179–2181
Powell JC, Twomey C, Jain R et al (2009) Association between Presenilin-1 and TRAF6 modulates regulated intramembrane proteolysis of the p75NTR neurotrophin receptor. J Neurochem 108(1):216–230
Berghoff J, Jaisimha AV, Duggan S et al (2015) Gamma-secretase-independent role for cadherin-11 in neurotrophin receptor p75 (p75(NTR)) mediated glioblastoma cell migration. Mol Cell Neurosci 69:41–53
Zampieri N, Xu CF, Neubert TA et al (2005) Cleavage of p75 neurotrophin receptor by alpha-secretase and gamma-secretase requires specific receptor domains. J Biol Chem 280(15):14563–14571
Lammich S, Okochi M, Takeda M et al (2002) Presenilin-dependent Intramembrane Proteolysis of CD44 Leads to the Liberation of Its Intracellular Domain and the Secretion of an Aβ-like Peptide. J Biol Chem 277(47):44754–44759
Wunderlich P, Glebov K, Kemmerling N et al (2013) Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and gamma-secretase-dependent intramembranous cleavage. J Biol Chem 288(46):33027–33036
Maetzel D, Denzel S, Mack B et al (2009) Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 11(2):162–171
Black RA, Rauch CT, Kozlosky CJ et al (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385(6618):729–733
Friedmann E, Hauben E, Maylandt K et al (2006) SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production. Nat Cell Biol 8(8):843–848
Chhibber-Goel J, Coleman-Vaughan C, Agrawal V et al (2016) γ-secretase activity is required for regulated intramembrane proteolysis of tumor necrosis factor (TNF) receptor 1 and TNF-mediated pro-apoptotic signaling. J Biol Chem 291(11):5971–5985
Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81(2):741–766
Small SA, Gandy S (2006) Sorting through the cell biology of Alzheimer’s disease: intracellular pathways to pathogenesis. Neuron 52(1):15–31
Tomita T, Iwatsubo T (2013) Structural biology of presenilins and signal peptide peptidases. J Biol Chem 288(21):14673–14680
Weidemann A, Eggert S, Reinhard FB et al (2002) A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry 41(8):2825–2835
Zhao G, Cui MZ, Mao G et al (2005) γ-cleavage is dependent on zeta-cleavage during the proteolytic processing of amyloid precursor protein within its transmembrane domain. J Biol Chem 280(45):37689–37697
Zhao G, Mao G, Tan J et al (2004) Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein. J Biol Chem 279(49):50647–50650
Okochi M, Fukumori A, Jiang J et al (2006) Secretion of the Notch-1 Aβ-like peptide during notch signaling. J Biol Chem 281(12):7890–7898
Beel AJ, Sanders CR (2008) Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol Life Sci 65(9):1311–1334
Sun L, Li X, Shi Y (2016) Structural biology of intramembrane proteases: mechanistic insights from rhomboid and S2P to γ-secretase. Curr Opin Struct Biol 37:97–107
Wolfe MS (2009) Intramembrane-cleaving Proteases. J Biol Chem 284(21):13969–13973
Martoglio B (2003) Intramembrane proteolysis and post-targeting functions of signal peptides. Biochem Soc Trans 31(Pt 6):1243–1247
Strisovsky K (2013) Structural and mechanistic principles of intramembrane proteolysis—lessons from rhomboids. FEBS J 280(7):1579–1603
Laurent SA, Hoffmann FS, Kuhn PH et al (2015) γ-secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun 6:7333
Fluhrer R, Steiner H, Haass C (2009) Intramembrane proteolysis by signal peptide peptidases: a comparative discussion of GXGD-type aspartyl proteases. J Biol Chem 284(21):13975–13979
Nyborg AC, Kornilova AY, Jansen K et al (2004) Signal peptide peptidase forms a homodimer that is labeled by an active site-directed γ-secretase inhibitor. J Biol Chem 279(15):15153–15160
Nyborg AC, Herl L, Berezovska O et al (2006) Signal peptide peptidase (SPP) dimer formation as assessed by fluorescence lifetime imaging microscopy (FLIM) in intact cells. Mol Neurodegeneration 1(1):1–8
Gertsik N, Chau D-M, Li Y-M (2015) γ-secretase inhibitors and modulators induce distinct conformational changes in the active sites of γ-secretase and signal peptide peptidase. ACS Chem Biol 10(8):1925–1931
Tomita T, Watabiki T, Takikawa R et al (2001) The first proline of PALP motif at the C terminus of presenilins is obligatory for stabilization, complex formation, and gamma-secretase activities of presenilins. J Biol Chem 276(35):33273–33281
Sato C, Takagi S, Tomita T et al (2008) The C-terminal PAL motif and transmembrane domain 9 of presenilin 1 are involved in the formation of the catalytic pore of the gamma-secretase. J Neurosci 28(24):6264–6271
Haass C, Selkoe DJ (1993) Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 75(6):1039–1042
Sherrington R, Rogaev EI, Liang Y et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375(6534):754–760
Tanzi RE, Kovacs DM, Kim TW et al (1996) The gene defects responsible for familial Alzheimer’s disease. Neurobiol Dis 3(3):159–168
Levy-Lahad E, Wasco W, Poorkaj P et al (1995) Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 269(5226):973–977
Yu G, Nishimura M, Arawaka S et al (2000) Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature 407(6800):48–54
Francis R, McGrath G, Zhang J et al (2002) aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell 3(1):85–97
Goutte C, Tsunozaki M, Hale VA et al (2002) APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci USA 99(2):775–779
Kimberly WT, LaVoie MJ, Ostaszewski BL et al (2003) Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci USA 100(11):6382–6387
De Strooper B (2003) Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex. Neuron 38(1):9–12
Kaether C, Haass C, Steiner H (2006) Assembly, trafficking and function of gamma-secretase. Neurodegener Dis 3(4–5):275–283
Ahn K, Shelton CC, Tian Y et al (2010) Activation and intrinsic γ-secretase activity of presenilin 1. Proc Natl Acad Sci 107(50):21435–21440
Takasugi N, Tomita T, Hayashi I et al (2003) The role of presenilin cofactors in the gamma-secretase complex. Nature 422(6930):438–441
Wolfe MS, Xia W, Ostaszewski BL et al (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398(6727):513–517
Herreman A, Hartmann D, Annaert W et al (1999) Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci USA 96(21):11872–11877
Dries DR, Yu G (2008) Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer’s disease. Curr Alzheimer Res 5(2):132–146
Yang DS, Tandon A, Chen F et al (2002) Mature glycosylation and trafficking of nicastrin modulate its binding to presenilins. J Biol Chem 277(31):28135–28142
Kimberly WT, LaVoie MJ, Ostaszewski BL et al (2002) Complex N-linked glycosylated nicastrin associates with active gamma-secretase and undergoes tight cellular regulation. J Biol Chem 277(38):35113–35117
De Strooper B (2005) Nicastrin: gatekeeper of the gamma-secretase complex. Cell 122(3):318–320
Bolduc DM, Montagna DR, Gu Y et al (2016) Nicastrin functions to sterically hinder gamma-secretase-substrate interactions driven by substrate transmembrane domain. Proc Natl Acad Sci USA 113(5):E509–E518
Shah S, Lee SF, Tabuchi K et al (2005) Nicastrin functions as a gamma-secretase-substrate receptor. Cell 122(3):435–447
Capell A, Beher D, Prokop S et al (2005) Gamma-secretase complex assembly within the early secretory pathway. J Biol Chem 280(8):6471–6478
Lee SF, Shah S, Li H et al (2002) Mammalian APH-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-beta precursor protein and Notch. J Biol Chem 277(47):45013–45019
Zhang X, Li Y, Xu H et al (2014) The γ-secretase complex: from structure to function. Front Cell Neurosci 8
Hébert SS, Serneels L, Dejaegere T et al (2004) Coordinated and widespread expression of γ-secretase in vivo: evidence for size and molecular heterogeneity. Neurobiol Dis 17(2):260–272
Kaether C, Scheuermann J, Fassler M et al (2007) Endoplasmic reticulum retention of the gamma-secretase complex component Pen2 by Rer1. EMBO Rep 8(8):743–748
Spasic D, Raemaekers T, Dillen K et al (2007) Rer1p competes with APH-1 for binding to nicastrin and regulates gamma-secretase complex assembly in the early secretory pathway. J Cell Biol 176(5):629–640
Dang S, Wu S, Wang J et al (2015) Cleavage of amyloid precursor protein by an archaeal presenilin homologue PSH. Proc Natl Acad Sci USA 112(11):3344–3349
Lu P, Bai XC, Ma D et al (2014) Three-dimensional structure of human gamma-secretase. Nature 512(7513):166–170
X-c Bai, Yan C, Yang G et al (2015) An atomic structure of human γ-secretase. Nature 525(7568):212–217
Ma G, Li T, Price DL et al (2005) APH-1a is the principal mammalian APH-1 isoform present in gamma-secretase complexes during embryonic development. J Neurosci 25(1):192–198
Mastrangelo P, Mathews PM, Chishti MA et al (2005) Dissociated phenotypes in presenilin transgenic mice define functionally distinct gamma-secretases. Proc Natl Acad Sci USA 102(25):8972–8977
Shirotani K, Tomioka M, Kremmer E et al (2007) Pathological activity of familial Alzheimer’s disease-associated mutant presenilin can be executed by six different gamma-secretase complexes. Neurobiol Dis 27(1):102–107
Shirotani K, Edbauer D, Prokop S et al (2004) Identification of distinct gamma-secretase complexes with different APH-1 variants. J Biol Chem 279(40):41340–41345
Meckler X, Checler F (2014) Visualization of specific gamma-secretase complexes using bimolecular fluorescence complementation. J Alzheimers Dis 40(1):161–176
Sannerud R, Esselens C, Ejsmont P et al (2016) Restricted location of PSEN2/gamma-Secretase determines substrate specificity and generates an intracellular aβ pool. Cell
Acx H, Chavez-Gutierrez L, Serneels L et al (2014) Signature amyloid beta profiles are produced by different gamma-secretase complexes. J Biol Chem 289(7):4346–4355
Bayer TA, Wirths O, Majtenyi K et al (2001) Key factors in Alzheimer’s disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol 11(1):1–11
Gouras GK, Tampellini D, Takahashi RH et al (2010) Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer’s disease. Acta Neuropathol 119(5):523–541
Pensalfini A, Albay R 3rd, Rasool S et al (2014) Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques. Neurobiol Dis 71:53–61
St George-Hyslop P, Fraser PE (2012) Assembly of the presenilin gamma-/epsilon-secretase complex. J Neurochem 120(1):84–88
Villa JC, Chiu D, Brandes AH et al (2014) Nontranscriptional role of Hif-1alpha in activation of gamma-secretase and notch signaling in breast cancer. Cell Rep 8(4):1077–1092
Wang X, Huang T, Zhao Y et al (2014) Sorting nexin 27 regulates Abeta production through modulating gamma-secretase activity. Cell Rep 9(3):1023–1033
Yan R, McCarthy JV (2010) Presenilin and γ-secretase activity: a viable therapeutic target for Alzheimer’s disease? Curr Signal Transduct Ther 5(2):128–140
Yan R, Farrelly S, McCarthy JV (2013) Presenilins are novel substrates for TRAF6-mediated ubiquitination. Cell Signal 25(9):1769–1779
Duggan SP, Yan R, McCarthy JV (2015) A ubiquitin-binding CUE domain in presenilin-1 enables interaction with K63-linked polyubiquitin chains. FEBS Lett 589(9):1001–1008
Uemura K, Kuzuya A, Shimozono Y et al (2007) GSK3beta activity modifies the localization and function of presenilin 1. J Biol Chem 282(21):15823–15832
Massey LK, Mah AL, Monteiro MJ (2005) Ubiquilin regulates presenilin endoproteolysis and modulates gamma-secretase components, Pen-2 and nicastrin. Biochem J 391(3):513–525
Li J, Pauley AM, Myers RL et al (2002) SEL-10 interacts with presenilin 1, facilitates its ubiquitination, and alters A-beta peptide production. J Neurochem 82(6):1540–1548
Nunan J, Shearman MS, Checler F et al (2001) The C-terminal fragment of the Alzheimer’s disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase. Eur J Biochem 268(20):5329–5336
Suzuki T, Nakaya T (2008) Regulation of amyloid beta-protein precursor by phosphorylation and protein interactions. J Biol Chem 283(44):29633–29637
Rebelo S, Domingues SC, Santos M et al (2013) Identification of a novel complex AbetaPP:Fe65:PP1 that regulates AbetaPP Thr668 phosphorylation levels. J Alzheimers Dis 35(4):761–775
Lee M-S, Kao S-C, Lemere CA et al (2003) APP processing is regulated by cytoplasmic phosphorylation. The Journal of Cell Biology 163(1):83–95
Iijima K, Ando K, Takeda S et al (2000) Neuron-specific phosphorylation of Alzheimer’s beta-amyloid precursor protein by cyclin-dependent kinase 5. J Neurochem 75(3):1085–1091
Suzuki N, Cheung TT, Cai XD et al (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264(5163):1336–1340
Aplin AE, Gibb GM, Jacobsen JS et al (1996) In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. J Neurochem 67(2):699–707
Standen CL, Brownlees J, Grierson AJ et al (2001) Phosphorylation of thr668 in the cytoplasmic domain of the Alzheimer’s disease amyloid precursor protein by stress-activated protein kinase 1b (Jun N-terminal kinase-3). J Neurochem 76(1):316–320
Taru H, Iijima K, Hase M et al (2002) Interaction of Alzheimer’s beta-amyloid precursor family proteins with scaffold proteins of the JNK signaling cascade. J Biol Chem 277(22):20070–20078
Vingtdeux V, Hamdane M, Gompel M et al (2005) Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. Neurobiol Dis 20(2):625–637
Chang K-A, Kim H-S, Ha T-Y et al (2006) Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. Mol Cell Biol 26(11):4327–4338
Parra LM, Hartmann M, Schubach S et al (2015) Distinct intracellular domain substrate modifications selectively regulate ectodomain cleavage of NRG1 or CD44. Mol Cell Biol 35(19):3381–3395
Annaert W, De Strooper B (2002) A cell biological perspective on Alzheimer’s disease. Annu Rev Cell Dev Biol 18:25–51
Traub LM, Bonifacino JS (2013) Cargo recognition in clathrin-mediated endocytosis. Cold Spring Harb Perspect Biol 5(11):a016790
Wakabayashi T, Craessaerts K, Bammens L et al (2009) Analysis of the [gamma]-secretase interactome and validation of its association with tetraspanin-enriched microdomains. Nat Cell Biol 11(11):1340–1346
Osenkowski P, Ye W, Wang R et al (2008) Direct and potent regulation of gamma-secretase by its lipid microenvironment. J Biol Chem 283(33):22529–22540
Urano Y, Hayashi I, Isoo N et al (2005) Association of active gamma-secretase complex with lipid rafts. J Lipid Res 46(5):904–912
Vetrivel KS, Cheng H, Lin W et al (2004) Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. J Biol Chem 279(43):44945–44954
Hur JY, Welander H, Behbahani H et al (2008) Active gamma-secretase is localized to detergent-resistant membranes in human brain. FEBS J 275(6):1174–1187
Vaccari T, Lu H, Kanwar R et al (2008) Endosomal entry regulates Notch receptor activation in Drosophila melanogaster. J Cell Biol 180(4):755–762
Gupta-Rossi N, Six E, LeBail O et al (2004) Monoubiquitination and endocytosis direct gamma-secretase cleavage of activated Notch receptor. J Cell Biol 166(1):73–83
Urra S, Escudero CA, Ramos P et al (2007) TrkA receptor activation by nerve growth factor induces shedding of the p75 neurotrophin receptor followed by endosomal gamma-secretase-mediated release of the p75 intracellular domain. J Biol Chem 282(10):7606–7615
Chhibber-Goel J, Coleman-Vaughan C, Agrawal V et al (2016) γ-secretase activity is required for regulated intramembrane proteolysis of tumor necrosis factor (TNF) receptor 1 and TNF-mediated pro-apoptotic signaling. J Biol Chem
Peric A, Annaert W (2015) Early etiology of Alzheimer’s disease: tipping the balance toward autophagy or endosomal dysfunction? Acta Neuropathol 129(3):363–381
Ueda N, Tomita T, Yanagisawa K et al (2016) Retromer and Rab2-dependent trafficking mediate PS1 degradation by proteasomes in endocytic disturbance. J Neurochem 137(4):647–658
St George-Hyslop PH (2000) Genetic factors in the genesis of Alzheimer’s disease. Ann NY Acad Sci 924:1–7
Godyń J, Jończyk J, Panek D et al (2016) Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol Rep 68(1):127–138
De Strooper B, Chavez Gutierrez L (2015) Learning by failing: ideas and concepts to tackle gamma-secretases in Alzheimer’s disease and beyond. Annu Rev Pharmacol Toxicol 55:419–437
De Strooper B (2014) Lessons from a failed γ-secretase Alzheimer trial. Cell 159(4):721–726
Vassar R, Bennett BD, Babu-Khan S et al (1999) β-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286(5440):735–741
Crump CJ, Johnson DS, Li Y-M (2013) Development and mechanism of γ-secretase modulators for Alzheimer’s disease. Biochemistry 52(19):3197–3216
Golde TE, Koo EH, Felsenstein KM et al (1828) γ-secretase inhibitors and modulators. Biochimica et Biophysica Acta (BBA)—Biomembranes 12:2898–2907 (2013)
Josien H (2002) Recent advances in the development of gamma-secretase inhibitors. Curr Opin Drug Discov Devel 5(4):513–525
Kreft AF, Martone R, Porte A (2009) Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer’s disease. J Med Chem 52(20):6169–6188
Karran E, Hardy J (2014) Antiamyloid therapy for Alzheimer’s disease—are we on the right road? N Engl J Med 370(4):377–378
Doody RS, Raman R, Farlow M et al (2013) A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 369(4):341–350
Henley DB, Sundell KL, Sethuraman G et al (2014) Safety profile of semagacestat, a gamma-secretase inhibitor: identity trial findings. Curr Med Res Opin 30(10):2021–2032
Coric V, van Dyck CH, Salloway S et al (2012) Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate alzheimer disease. Arch Neurol 69(11):1430–1440
Albright CF, Dockens RC, Meredith JE et al (2013) Pharmacodynamics of selective inhibition of γ-secretase by avagacestat. J Pharmacol Exp Ther 344(3):686–695
Probst G, Aubele DL, Bowers S et al (2013) Discovery of (R)-4-Cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-Cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase inhibitors that selectively inhibit the production of amyloid-β over Notch. J Med Chem 56(13):5261–5274
Weggen S, Eriksen JL, Das P et al (2001) A subset of NSAIDs lower amyloidogenic A[beta]42 independently of cyclooxygenase activity. Nature 414(6860):212–216
Lim GP, Yang F, Chu T et al (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci 20(15):5709–5714
Das C, Berezovska O, Diehl TS et al (2003) Designed helical peptides inhibit an intramembrane protease. J Am Chem Soc 125(39):11794–11795
Mohr OL (1919) character changes caused by mutation of an entire region of a chromosome in Drosophila. Genetics 4(3):275–282
Groeneweg JW, Foster R, Growdon WB et al (2014) Notch signaling in serous ovarian cancer. J Ovarian Res 7:95
Hales EC, Taub JW, Matherly LH (2014) New insights into Notch1 regulation of the PI3 K-AKT-mTOR1 signaling axis: targeted therapy of gamma-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal 26(1):149–161
Takebe N, Nguyen D, Yang SX (2014) Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther 141(2):140–149
Reynolds TC, Smith SD, Sklar J (1987) Analysis of DNA surrounding the breakpoints of chromosomal translocations involving the beta T cell receptor gene in human lymphoblastic neoplasms. Cell 50(1):107–117
Ellisen LW, Bird J, West DC et al (1991) TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66(4):649–661
Mao L (2015) NOTCH mutations: multiple faces in human malignancies. Cancer Prev Res (Phila) 8(4):259–261
Mutvei AP, Fredlund E, Lendahl U (2015) Frequency and distribution of Notch mutations in tumor cell lines. BMC Cancer 15:311
Weng AP, Ferrando AA, Lee W et al (2004) Activating mutations of Notch1 in human T cell acute lymphoblastic leukemia. Science 306(5694):269–271
Liu J, Shen JX, Wen XF et al (2016) Targeting Notch degradation system provides promise for breast cancer therapeutics. Crit Rev Oncol Hematol
Guilmeau S (2012) Notch signaling and intestinal cancer. Adv Exp Med Biol 727:272–288
Bertrand FE, Angus CW, Partis WJ et al (2012) Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch. Cell Cycle 11(23):4344–4351
Avila JL, Kissil JL (2013) Notch signaling in pancreatic cancer: oncogene or tumor suppressor? Trends Mol Med 19(5):320–327
Su Q, Xin L (2016) Notch signaling in prostate cancer: refining a therapeutic opportunity. Histol Histopathol 31(2):149–157
Lino MM, Merlo A, Boulay JL (2010) Notch signaling in glioblastoma: a developmental drug target? BMC Med 8:72
Weijzen S, Rizzo P, Braid M et al (2002) Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 8(9):979–986
Stylianou S, Clarke RB, Brennan K (2006) Aberrant activation of notch signaling in human breast cancer. Cancer Res 66(3):1517–1525
Ranganathan P, Weaver KL, Capobianco AJ (2011) Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 11(5):338–351
Koch U, Radtke F (2007) Notch and cancer: a double-edged sword. Cell Mol Life Sci 64(21):2746–2762
Andersson ER, Lendahl U (2014) Therapeutic modulation of Notch signalling—are we there yet? Nat Rev Drug Discov 13(5):357–378
Gottlinger H, Johnson J, Riethmuller G (1986) Biochemical and epitope analysis of the 17-1A membrane antigen. Hybridoma 5(1):S29–S37
Herlyn M, Steplewski Z, Herlyn D et al (1979) Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 76(3):1438–1442
Schnell U, Cirulli V (1828) Giepmans BN (2013) EpCAM: structure and function in health and disease. Biochim Biophys Acta 8:1989–2001
Osta WA, Chen Y, Mikhitarian K et al (2004) EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64(16):5818–5824
Al-Hajj M, Wicha MS, Benito-Hernandez A et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983–3988
Spizzo G, Went P, Dirnhofer S et al (2004) High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 86(3):207–213
Hachmeister M, Bobowski KD, Hogl S et al (2013) Regulated intramembrane proteolysis and degradation of murine epithelial cell adhesion molecule mEpCAM. PLoS ONE 8(8):e71836
Denzel S, Maetzel D, Mack B et al (2009) Initial activation of EpCAM cleavage via cell-to-cell contact. BMC Cancer 9:402
Nubel T, Preobraschenski J, Tuncay H et al (2009) Claudin-7 regulates EpCAM-mediated functions in tumor progression. Mol Cancer Res 7(3):285–299
Kuhn S, Koch M, Nubel T et al (2007) A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res 5(6):553–567
van der Gun BT, Melchers LJ, Ruiters MH et al (2010) EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31(11):1913–1921
Patriarca C, Macchi RM, Marschner AK et al (2012) Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 38(1):68–75
Gao J, Liu X, Yang F et al (2015) By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis. Oncotarget 6(29):27187–27198
Gilboa-Geffen A, Hamar P, Le MT et al (2015) Gene knockdown by EpCAM Aptamer-siRNA chimeras suppresses epithelial breast cancers and their tumor-initiating cells. Mol Cancer Ther 14(10):2279–2291
Sankpal NV, Mayfield JD, Willman MW et al (2011) Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion. Breast Cancer Res 13(6):R124
Gao J, Yan Q, Liu S et al (2014) Knockdown of EpCAM enhances the chemosensitivity of breast cancer cells to 5-fluorouracil by downregulating the antiapoptotic factor Bcl-2. PLoS ONE 9(7):e102590
Ralhan R, Cao J, Lim T et al (2010) EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. BMC Cancer 10:331
He HC, Kashat L, Kak I et al (2012) An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma. PLoS ONE 7(9):e42893
Kunavisarut T, Kak I, Macmillan C et al (2012) Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma. BMC Cancer 12:523
Chopra A (2004) 64Cu-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated IRDye 800CW (a near-infrared fluorescence dye) coupled to mAb7, an anti-epithelial cell adhesion molecule monoclonal antibody. In: Molecular imaging and contrast agent database (MICAD). Bethesda (MD)
Leung K (2004) 68 Ga-Labeled anti-EpCAM diabody against epithelial cell adhesion molecule. In: Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD)
Leung K (2004) DiD-Labeled anti-EpCAM-directed NK-92-scFv(MOC31) zeta cells. In: Molecular imaging and contrast agent database (MICAD). Bethesda (MD)
Rybalov M, Ananias HJ, Hoving HD et al (2014) PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy. Int J Mol Sci 15(4):6046–6061
Kanwar JR, Roy K, Kanwar RK (2011) Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol 46(6):459–477
Flatmark K, Guldvik IJ, Svensson H et al (2013) Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies. Int J Cancer 133(6):1497–1506
Zhu B, Wu G, Robinson H et al (2013) Tumor margin detection using quantitative NIRF molecular imaging targeting EpCAM validated by far red gene reporter iRFP. Mol Imaging Biol 15(5):560–568
Reichardt L (2006) Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 361(1473):1545–1564
Roux P, Barker P (2002) Neurotrophin signaling through the p75 neurotrophin receptor. Prog Neurobiol 67(3):203–233
Hamanoue M, Middleton G, Wyatt S et al (1999) p75-mediated NF-kappaB activation enhances the survival response of developing sensory neurons to nerve growth factor. Mol Cell Neurosci 14(1):28–40
Roux P, Bhakar A, Kennedy T et al (2001) The p75 neurotrophin receptor activates Akt (protein kinase B) through a phosphatidylinositol 3-kinase-dependent pathway. J Biol Chem 276(25):23097–23104
Weskamp G, Schlöndorff J, Lum L et al (2004) Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75NTR). J Biol Chem 279(6):4241–4249
Kanning K, Hudson M, Amieux P et al (2003) Proteolytic processing of the p75 neurotrophin receptor and two homologs generates C-terminal fragments with signaling capability. J Neurosci: Official J Soc Neurosci 23(13):5425–5436
Jung K-M, Tan S, Landman N et al (2003) Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor. J Biol Chem 278(43):42161–42169
Parkhurst C, Zampieri N, Chao M (2010) Nuclear localization of the p75 neurotrophin receptor intracellular domain. J Biol Chem 285(8):5361–5368
Podlesniy P, Kichev A, Pedraza C et al (2006) Pro-NGF from Alzheimer’s disease and normal human brain displays distinctive abilities to induce processing and nuclear translocation of intracellular domain of p75NTR and apoptosis. Am J Pathol 169(1):119–131
Kenchappa R, Zampieri N, Chao M et al (2006) Ligand-dependent cleavage of the P75 neurotrophin receptor is necessary for NRIF nuclear translocation and apoptosis in sympathetic neurons. Neuron 50(2):219–232
Domeniconi M, Zampieri N, Spencer T et al (2005) MAG induces regulated intramembrane proteolysis of the p75 neurotrophin receptor to inhibit neurite outgrowth. Neuron 46(6):849–855
Krygier S, Djakiew D (2002) Neurotrophin receptor p75(NTR) suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int J Cancer 98(1):1–7
Arrighi N, Bodei S, Zani D et al (2010) Nerve growth factor signaling in prostate health and disease. Growth Factors 28(3):191–201
Marchetti D, Aucoin R, Blust J et al (2004) p75 neurotrophin receptor functions as a survival receptor in brain-metastatic melanoma cells. J Cell Biochem 91(1):206–215
Marchetti D, Mrak R, Paulsen D et al (2007) Neurotrophin receptors and heparanase: a functional axis in human medulloblastoma invasion. J Exp Clin Cancer Res CR 26(1):5–23
Boiko A, Razorenova O, van de Rijn M et al (2010) Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466(7302):133–137
Denkins Y, Reiland J, Roy M et al (2004) Brain metastases in melanoma: roles of neurotrophins. Neuro-oncology 6(2):154–165
Johnston A, Lun X, Rahn J et al (2007) The p 75 neurotrophin receptor is a central regulator of glioma invasion. PLoS Bio l5(8)
Wang X, Cui M, Wang L et al (2010) Inhibition of neurotrophin receptor p75 intramembran proteolysis by gamma-secretase inhibitor reduces medulloblastoma spinal metastasis. Biochem Biophys Res Commun 403(3–4):264–269
Forsyth PA, Krishna N, Lawn S et al (2014) p75 neurotrophin receptor cleavage by alpha- and gamma-secretases is required for neurotrophin-mediated proliferation of brain tumor-initiating cells. J Biol Chem 289(12):8067–8085
Descamps S, Toillon R, Adriaenssens E et al (2001) Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J Biol Chem 276(21):17864–17870
Verbeke S, Meignan S, Lagadec C et al (2010) Overexpression of p75(NTR) increases survival of breast cancer cells through p21(waf1). Cell Signal 22(12):1864–1873
Wang L, Rahn J, Lun X et al (2008) Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p 75 neurotrophin receptor. PLoS Biol 6(11)
Zhou J, Jain S, Azad AK et al (2016) Notch and TGFbeta form a positive regulatory loop and regulate EMT in epithelial ovarian cancer cells. Cell Signal 28(8):838–849
Dinicola S, Pasqualato A, Proietti S et al (2016) Paradoxical E-cadherin increase in 5FU-resistant colon cancer is unaffected during mesenchymal-epithelial reversion induced by gamma-secretase inhibition. Life Sci 145:174–183
Rosati E, Sabatini R, De Falco F et al (2013) gamma-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation. Int J Cancer 132(8):1940–1953
Zou YH, Cao YQ, Wang LX et al (2011) γ-secretase inhibitor up-regulates vascular endothelial growth factor receptor-2 and endothelial nitric oxide synthase. Exp Ther Med 2(4):725–729
Kalantari E, Saeidi H, Kia NS et al (2013) Effect of DAPT, a gamma secretase inhibitor, on tumor angiogenesis in control mice. Adv Biomed Res 2:83
Maraver A, Fernandez-Marcos PJ, Herranz D et al (2012) Therapeutic effect of gamma-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell 22(2):222–234
Cullion K, Draheim KM, Hermance N et al (2009) Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood 113(24):6172–6181
Engin F, Bertin T, Ma O et al (2009) Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet 18(8):1464–1470
Meng RD, Shelton CC, Li Y-M et al (2009) γ-secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Can Res 69(2):573–582
Yuan X, Wu H, Xu H et al (2015) Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett 369(1):20–27
Kumar R, Juillerat-Jeanneret L, Golshayan D (2016) Notch antagonists: potential modulators of cancer and inflammatory diseases. J Med Chem
De Jesus-Acosta A, Laheru D, Maitra A et al (2014) A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Invest New Drugs 32(4):739–745
Lee SM, Moon J, Redman BG et al (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121(3):432–440
Papayannidis C, DeAngelo DJ, Stock W et al (2015) A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J 5:e350
Messersmith WA, Shapiro GI, Cleary JM et al (2015) A Phase I, dose-finding study in patients with advanced solid malignancies of the oral gamma-secretase inhibitor PF-03084014. Clin Cancer Res 21(1):60–67
Fouladi M, Stewart CF, Olson J et al (2011) Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol 29(26):3529–3534
Krop I, Demuth T, Guthrie T et al (2012) Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 30(19):2307–2313
Piha-Paul SA, Munster PN, Hollebecque A et al (2015) Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. Eur J Cancer 51(14):1865–1873
Hoffman LM, Fouladi M, Olson J et al (2015) Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nerv Syst 31(8):1283–1289
LoConte NK, Razak AR, Ivy P et al (2015) A multicenter phase 1 study of gamma -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest New Drugs 33(1):169–176
Diaz-Padilla I, Hirte H, Oza AM et al (2013) A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Invest New Drugs 31(5):1182–1191
Richter S, Bedard PL, Chen EX et al (2014) A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Invest New Drugs 32(2):243–249
Tolcher AW, Messersmith WA, Mikulski SM et al (2012) Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 30(19):2348–2353
McAuliffe SM, Morgan SL, Wyant GA et al (2012) Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci USA 109(43):E2939–E2948
Singh A, Zapata MC, Choi YS et al (2014) GSI promotes vincristine-induced apoptosis by enhancing multi-polar spindle formation. Cell Cycle 13(1):157–166
Woorons X, Mollard P, Pichon A et al (2008) Effects of a 4-week training with voluntary hypoventilation carried out at low pulmonary volumes. Respir Physiol Neurobiol 160(2):123–130
Arasada RR, Amann JM, Rahman MA et al (2014) EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling. Cancer Res 74(19):5572–5584
Li LC, Wang DL, Wu YZ et al (2015) Gastric tumor-initiating CD44+ cells and epithelial-mesenchymal transition are inhibited by gamma-secretase inhibitor DAPT. Oncol Lett 10(5):3293–3299
Ni J, Cozzi P, Hao J et al (2013) Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol 45(12):2736–2748
Yahyanejad S, Theys J, Vooijs M (2016) Targeting Notch to overcome radiation resistance. Oncotarget 7(7):7610–7628
Huang X, Qian Y, Wu H et al (2015) Aberrant expression of osteopontin and E-cadherin indicates radiation resistance and poor prognosis for patients with cervical carcinoma. J Histochem Cytochem 63(2):88–98
Taylor IC, Hutt-Cabezas M, Brandt WD et al (2015) Disrupting Notch slows diffuse intrinsic pontine glioma growth, enhances radiation sensitivity, and shows combinatorial efficacy with bromodomain inhibition. J Neuropathol Exp Neurol 74(8):778–790
Mizugaki H, Sakakibara-Konishi J, Ikezawa Y et al (2012) γ-secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer. Br J Cancer 106(12):1953–1959
Vermezovic J, Adamowicz M, Santarpia L et al (2015) Notch is a direct negative regulator of the DNA-damage response. Nat Struct Mol Biol 22(5):417–424
Panaccione A, Chang MT, Carbone BE et al (2016) NOTCH1 and SOX10 are essential for proliferation and radiation resistance of cancer stem-like cells in adenoid cystic carcinoma. Clin Cancer Res 22(8):2083–2095
Debeb BG, Cohen EN, Boley K et al (2012) Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat 134(2):495–510
Jowett PL, Nicohlson SS, Gamble GA (1986) Tissue levels of atrazine in a case of bovine poisoning. Vet Hum Toxicol 28(6):539–540
Kanu OO, Hughes B, Di C et al (2009) Glioblastoma multiforme oncogenomics and signaling pathways. Clin Med Oncol 3:39–52
Kanu OO, Mehta A, Di C et al (2009) Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets 13(6):701–718
Yahyanejad S, King H, Iglesias VS et al (2016) NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget
Natsumeda M, Maitani K, Liu Y et al (2015) Targeting Notch signaling and autophagy increases cytotoxicity in glioblastoma neurospheres. Brain Pathol
Lundy EG, Sorokin CF, Meltz SK et al (1977) Reversible inhibition of human peripheral lymphocyte DNA synthesis by an extract of breast cancer cell line SKBR-3. J Surg Res 22(6):654–659
Han J, Shen Q (2012) Targeting gamma-secretase in breast cancer. Breast Cancer 4:83–90
Demehri S, Turkoz A, Kopan R (2009) Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell 16(1):55–66
Cheng YL, Choi Y, Sobey CG et al (2015) Emerging roles of the gamma-secretase-notch axis in inflammation. Pharmacol Ther 147:80–90
Saura CA (2010) Presenilin/γ-secretase and inflammation. Front Aging Neurosci 2:16
Tournoy J, Bossuyt X, Snellinx A et al (2004) Partial loss of presenilins causes seborrheic keratosis and autoimmune disease in mice. Hum Mol Genet 13(13):1321–1331
Li T, Wen H, Brayton C et al (2007) Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. J Neurosci 27(40):10849–10859
Maraver A, Tadokoro CE, Badura ML et al (2007) Effect of presenilins in the apoptosis of thymocytes and homeostasis of CD8+T cells. Blood 110(9):3218–3225
Yagi T, Giallourakis C, Mohanty S et al (2008) Defective signal transduction in B lymphocytes lacking presenilin proteins. Proc Natl Acad Sci USA 105(3):979–984
Beglopoulos V, Sun X, Saura CA et al (2004) Reduced β-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. J Biol Chem 279(45):46907–46914
Dong S, Li C, Wu P et al (2007) Environment enrichment rescues the neurodegenerative phenotypes in presenilins-deficient mice. Eur J Neurosci 26(1):101–112
Jiang X, Zhang D, Shi J et al (2009) Increased inflammatory response both in brain and in periphery in presenilin 1 and presenilin 2 conditional double knock-out mice. J Alzheimers Dis 18(3):515–523
Jayadev S, Case A, Eastman AJ et al (2010) Presenilin 2 is the predominant γ-secretase in microglia and modulates cytokine release. PLoS ONE 5(12):e15743
Parks WC, Wilson CL, Lopez-Boado YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4(8):617–629
Garton KJ, Gough PJ, Raines EW (2006) Emerging roles for ectodomain shedding in the regulation of inflammatory responses. J Leukoc Biol 79(6):1105–1116
Murphy G, Murthy A, Khokha R (2008) Clipping, shedding and RIPping keep immunity on cue. Trends Immunol 29(2):75–82
Lleo A, Saura CA (2011) gamma-secretase substrates and their implications for drug development in Alzheimer’s disease. Curr Top Med Chem 11(12):1513–1527
Carter C (2011) Alzheimer’s disease: APP, Gamma Secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and their relationships with herpes simplex, C. Pneumoniae, Other suspect pathogens, and the immune system. Int J Alzheimers Dis 2011:501862
Garlind A, Brauner A, Hojeberg B et al (1999) Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer’s disease patients. Brain Res 826(1):112–116
Chalaris A, Gewiese J, Paliga K et al (1803) ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by gamma-secretase. Biochim Biophys Acta 2:234–245 (2010)
Glenn G, van der Geer P (2008) Toll-like receptors stimulate regulated intramembrane proteolysis of the CSF-1 receptor through Erk activation. FEBS Lett 582(6):911–915
Agrawal V, Sawhney N, Hickey E et al (2015) Loss of presenilin 2 function is associated with defective LPS-mediated innate immune responsiveness. Mol Neurobiol 53(5):3428–3438
Hickman SE, El Khoury J (2014) TREM2 and the neuroimmunology of Alzheimer’s disease. Biochem Pharmacol 88(4):495–498
Wang Y, Ulland TK, Ulrich JD et al (2016) TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 213(5):667–675
Yuan P, Condello C, Keene CD et al (2016) TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90(4):724–739
Glebov K, Wunderlich P, Karaca I et al (2016) Functional involvement of γ-secretase in signaling of the triggering receptor expressed on myeloid cells-2 (TREM2). J Neuroinflammation 13(1):1–7
Schulte A, Schulz B, Andrzejewski MG et al (2007) Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by alpha- and gamma-secretases. Biochem Biophys Res Commun 358(1):233–240
Mambole A, Baruch D, Nusbaum P et al (2008) The cleavage of neutrophil leukosialin (CD43) by cathepsin G releases its extracellular domain and triggers its intramembrane proteolysis by presenilin/gamma-secretase. J Biol Chem 283(35):23627–23635
Pelletier L, Guillaumot P, Freche B et al (2006) Gamma-secretase-dependent proteolysis of CD44 promotes neoplastic transformation of rat fibroblastic cells. Cancer Res 66(7):3681–3687
Fukumoto N, Shimaoka T, Fujimura H et al (2004) Critical roles of CXC chemokine ligand 16/scavenger receptor that binds phosphatidylserine and oxidized lipoprotein in the pathogenesis of both acute and adoptive transfer experimental autoimmune encephalomyelitis. J Immunol 173(3):1620–1627
Jong A, Wu CH, Shackleford GM et al (2008) Involvement of human CD44 during Cryptococcus neoformans infection of brain microvascular endothelial cells. Cell Microbiol 10(6):1313–1326
Bacsa S, Karasneh G, Dosa S et al (2011) Syndecan-1 and syndecan-2 play key roles in herpes simplex virus type-1 infection. J Gen Virol 92(Pt 4):733–743
de Witte L, Bobardt M, Chatterji U et al (2007) Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc Natl Acad Sci 104(49):19464–19469
Schulz JG, Annaert W, Vandekerckhove J et al (2003) Syndecan 3 intramembrane proteolysis is presenilin/gamma-secretase-dependent and modulates cytosolic signaling. J Biol Chem 278(49):48651–48657
Persson BD, Schmitz NB, Santiago C et al (2010) Structure of the extracellular portion of CD46 provides insights into its interactions with complement proteins and pathogens. PLoS Pathog 6(9):e1001122
Weyand NJ, Calton CM, Higashi DL et al (2010) Presenilin/gamma-secretase cleaves CD46 in response to Neisseria infection. J Immunol 184(2):694–701
Tsao PN, Wei SC, Huang MT et al (2011) Lipopolysaccharide-induced Notch signaling activation through JNK-dependent pathway regulates inflammatory response. J Biomed Sci 18:56
Zhang W, Zhang X, Sheng A, Weng C, Zhu T, Zhao W, Li C (2015) γ-secretase inhibitor alleviates acute airway inflammation of allergic asthma in mice by downregulating Th17 cell differentiation. Mediators of Inflammation 2015 (2015):258168
Varfolomeev E, Goncharov T, Vucic D (2015) Roles of c-IAP proteins in TNF receptor family activation of NF-kappaB signaling. Methods Mol Biol 1280:269–282
Muppidi JR, Tschopp J, Siegel RM (2004) Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 21(4):461–465
Tchikov V, Bertsch U, Fritsch J et al (2011) Subcellular compartmentalization of TNF receptor-1 and CD95 signaling pathways. Eur J Cell Biol 90(6–7):467–475
Schneider-Brachert W, Heigl U, Ehrenschwender M (2013) Membrane trafficking of death receptors: implications on signalling. Int J Mol Sci 14(7):14475–14503
Cabal-Hierro L, Lazo PS (2012) Signal transduction by tumor necrosis factor receptors. Cell Signal 24(6):1297–1305
Irannejad R, von Zastrow M (2014) GPCR signaling along the endocytic pathway. Curr Opin Cell Biol 27:109–116
Tsvetanova NG, Irannejad R, von Zastrow M (2015) G protein-coupled receptor (GPCR) signaling via heterotrimeric G proteins from endosomes. J Biol Chem 290(11):6689–6696
Saleh AZ, Fang AT, Arch AE et al (2004) Regulated proteolysis of the IFNaR2 subunit of the interferon-alpha receptor. Oncogene 23(42):7076–7086
Hemming ML, Elias JE, Gygi SP et al (2008) Proteomic profiling of ?-secretase substrates and mapping of substrate requirements. PLoS Biol 6(10):e257
Carey BW, Kim DY, Kovacs DM (2007) Presenilin/gamma-secretase and alpha-secretase-like peptidases cleave human MHC Class I proteins. Biochem J 401(1):121–127
Saxena MT, Schroeter EH, Mumm JS et al (2001) Murine notch homologs (N1-4) undergo presenilin-dependent proteolysis. J Biol Chem 276(43):40268–40273
Okochi M, Steiner H, Fukumori A et al (2002) Presenilins mediate a dual intramembranous γ-secretase cleavage of Notch-1. EMBO J 21(20):5408–5416
Shimizu K, Chiba S, Hosoya N et al (2000) Binding of Delta1, Jagged1, and Jagged2 to Notch2 rapidly induces cleavage, nuclear translocation, and hyperphosphorylation of Notch2. Mol Cell Biol 20(18):6913–6922
Wang H, Li ZY, Liu Y et al (2011) Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 17(1):96–104
May P, Reddy YK, Herz J (2002) Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. J Biol Chem 277(21):18736–18743
Hoe HS, Rebeck GW (2005) Regulation of ApoE receptor proteolysis by ligand binding. Brain Res Mol Brain Res 137(1–2):31–39
Lee HJ, Jung KM, Huang YZ et al (2002) Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. J Biol Chem 277(8):6318–6323
Tuffereau C, Bénéjean J, Blondel D et al (1998) Low-affinity nerve-growth factor receptor (P75NTR) can serve as a receptor for rabies virus. The EMBO J 17(24):7250–7259
Kim DY, Ingano LA, Kovacs DM (2002) Nectin-1alpha, an immunoglobulin-like receptor involved in the formation of synapses, is a substrate for presenilin/gamma-secretase-like cleavage. J Biol Chem 277(51):49976–49981
Tousseyn T, Thathiah A, Jorissen E et al (2009) ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the γ-secretase. J Biol Chem 284(17):11738–11747
Wilke GA, Bubeck Wardenburg J (2010) Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated cellular injury. Proc Natl Acad Sci USA 107(30):13473–13478
Acknowledgements
We apologise to all colleagues whose work has not been discussed or cited owing to space limitations. This work was supported and funded by grants from Science Foundation Ireland (02/IN1/B218 and 09/IN.1/B2624) and a student bursary to CCV from the College of Science Engineering & Food Science, University College Cork.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Coleman-Vaughan, C., Mal, A., De, A., McCarthy, J.V. (2017). The γ-Secretase Protease Complexes in Neurodegeneration, Cancer and Immunity. In: Chakraborti, S., Dhalla, N. (eds) Pathophysiological Aspects of Proteases. Springer, Singapore. https://doi.org/10.1007/978-981-10-6141-7_3
Download citation
DOI: https://doi.org/10.1007/978-981-10-6141-7_3
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-6140-0
Online ISBN: 978-981-10-6141-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)